Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201198 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL418792 | 0.79 | NPC1 (0.60) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL5743889 | 0.78 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL29500516 | 0.78 | LMNA (0.57) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL18537879 | 0.78 | LMNA (0.57) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL421032 | 0.77 | SCD (0.58) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL25956596 | 0.77 | IRAK4 (0.83) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL17488032 | 0.76 | RAB9A (0.67) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL4090435 | 0.76 | IRAK4 (0.50) | SMN1; SMN2NPC1KMT2ARAB9AMEN1 | |
| SCHEMBL19446745 | 0.76 | GRM1 (0.43) | SMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | SMN1; SMN2 3959/4885NPC1 2626/4885KMT2A 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.